{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:07:32Z","timestamp":1783955252395,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100018439","name":"SK Life Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018439","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40266-024-01102-3","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T07:02:27Z","timestamp":1709708547000},"page":"251-260","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety and Efficacy of Cenobamate for the Treatment of Focal Seizures in Older Patients: Post Hoc Analysis of a Phase III, Multicenter, Open-Label Study"],"prefix":"10.1007","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct02535091","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2461-8457","authenticated-orcid":false,"given":"Rebecca","family":"O\u2019Dwyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarence T.","family":"Wade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Guggilam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Rosenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"issue":"3","key":"1102_CR1","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1528-1157.1993.tb02586.x","volume":"34","author":"WA Hauser","year":"1993","unstructured":"Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935\u20131984. Epilepsia. 1993;34(3):453\u201368. https:\/\/doi.org\/10.1111\/j.1528-1157.1993.tb02586.x.","journal-title":"Epilepsia"},{"issue":"9848","key":"1102_CR2","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/s0140-6736(12)61517-7","volume":"380","author":"IE Leppik","year":"2012","unstructured":"Leppik IE, Walczak TS, Birnbaum AK. Challenges of epilepsy in elderly people. Lancet. 2012;380(9848):1128\u201330. https:\/\/doi.org\/10.1016\/s0140-6736(12)61517-7.","journal-title":"Lancet"},{"key":"1102_CR3","unstructured":"Roberts AW, Ogunwole SU, Blakeslee L, Rabe MA, US Census Bureau. The Population 65 Years and Older in the United States: 2016. American Community Survey Reports. 2018. https:\/\/www.census.gov\/content\/dam\/Census\/library\/publications\/2018\/acs\/ACS-38.pdf. Accessed 9 Dec 2022."},{"issue":"1","key":"1102_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.14581\/jer.19003","volume":"9","author":"SK Lee","year":"2019","unstructured":"Lee SK. Epilepsy in the elderly: treatment and consideration of comorbid diseases. J Epilepsy Res. 2019;9(1):27\u201335. https:\/\/doi.org\/10.14581\/jer.19003.","journal-title":"J Epilepsy Res"},{"issue":"11","key":"1102_CR5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s11910-016-0696-8","volume":"16","author":"PV Motika","year":"2016","unstructured":"Motika PV, Spencer DC. Treatment of epilepsy in the elderly. Curr Neurol Neurosci Rep. 2016;16(11):96. https:\/\/doi.org\/10.1007\/s11910-016-0696-8.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"Suppl 1","key":"1102_CR6","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.eplepsyres.2005.07.017","volume":"68","author":"E Perucca","year":"2006","unstructured":"Perucca E, Berlowitz D, Birnbaum A, et al. Pharmacological and clinical aspects of antiepileptic drug use in the elderly. Epilepsy Res. 2006;68(Suppl 1):S49\u201363. https:\/\/doi.org\/10.1016\/j.eplepsyres.2005.07.017.","journal-title":"Epilepsy Res"},{"issue":"10","key":"1102_CR7","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1080\/17425255.2020.1806236","volume":"16","author":"R Roberti","year":"2020","unstructured":"Roberti R, Palleria C, Nesci V, et al. Pharmacokinetic considerations about antiseizure medications in the elderly. Expert Opin Drug Metab Toxicol. 2020;16(10):983\u201395. https:\/\/doi.org\/10.1080\/17425255.2020.1806236.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1102_CR8","unstructured":"XCOPRI\u00ae (cenobamate tablets), for oral use, CV [prescribing information]. Paramus: SK Life Science, Inc.; 2024."},{"key":"1102_CR9","unstructured":"Ontozry [summary of product characteristics]. Rome: Angelini Pharma S.p.A; 2023."},{"issue":"4","key":"1102_CR10","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s13318-020-00615-7","volume":"45","author":"L Vernillet","year":"2020","unstructured":"Vernillet L, Greene SA, Kim HW, Melnick SM, Glenn K. Mass balance, metabolism, and excretion of cenobamate, a new antiepileptic drug, after a single oral administration in healthy male subjects. Eur J Drug Metab Pharmacokinet. 2020;45(4):513\u201322. https:\/\/doi.org\/10.1007\/s13318-020-00615-7.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1102_CR11","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s40120-022-00400-5","volume":"11","author":"MC Smith","year":"2022","unstructured":"Smith MC, Klein P, Krauss GL, et al. Dose adjustment of concomitant antiseizure medications during cenobamate treatment: expert opinion consensus recommendations. Neurol Ther. 2022;11:1705\u201320. https:\/\/doi.org\/10.1007\/s40120-022-00400-5.","journal-title":"Neurol Ther."},{"issue":"12","key":"1102_CR12","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1111\/epi.17092","volume":"62","author":"WE Rosenfeld","year":"2021","unstructured":"Rosenfeld WE, Abou-Khalil B, Aboumatar S, et al. Post-hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: effects of dose adjustments of concomitant antiseizure medications. Epilepsia. 2021;62(12):3016\u201328. https:\/\/doi.org\/10.1111\/epi.17092.","journal-title":"Epilepsia"},{"issue":"22","key":"1102_CR13","doi-asserted-by":"publisher","first-page":"e2311","DOI":"10.1212\/wnl.0000000000009530","volume":"94","author":"SS Chung","year":"2020","unstructured":"Chung SS, French JA, Kowalski J, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94(22):e2311\u201322. https:\/\/doi.org\/10.1212\/wnl.0000000000009530.","journal-title":"Neurology"},{"issue":"1","key":"1102_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","volume":"19","author":"GL Krauss","year":"2020","unstructured":"Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(1):38\u201348. https:\/\/doi.org\/10.1016\/S1474-4422(19)30399-0.","journal-title":"Lancet Neurol"},{"issue":"6","key":"1102_CR15","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/epi.16525","volume":"61","author":"MR Sperling","year":"2020","unstructured":"Sperling MR, Klein P, Aboumatar S, et al. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia. 2020;61(6):1099\u2013108. https:\/\/doi.org\/10.1111\/epi.16525.","journal-title":"Epilepsia"},{"issue":"12","key":"1102_CR16","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1111\/epi.17091","volume":"62","author":"MR Sperling","year":"2021","unstructured":"Sperling MR, Abou-Khalil B, Aboumatar S, et al. Efficacy of cenobamate for uncontrolled focal seizures: post-hoc analysis of a phase 3, multicenter, open-label study. Epilepsia. 2021;62(12):3005\u201315. https:\/\/doi.org\/10.1111\/epi.17091.","journal-title":"Epilepsia"},{"issue":"10","key":"1102_CR17","doi-asserted-by":"publisher","first-page":"e989","DOI":"10.1212\/wnl.0000000000200792","volume":"99","author":"P Klein","year":"2022","unstructured":"Klein P, Aboumatar S, Brandt C, et al. Long-term efficacy and safety from an open-label extension of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2022;99(10):e989\u201398. https:\/\/doi.org\/10.1212\/wnl.0000000000200792.","journal-title":"Neurology"},{"issue":"9","key":"1102_CR18","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1111\/epi.17007","volume":"62","author":"JA French","year":"2021","unstructured":"French JA, Chung SS, Krauss GL, et al. Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open-label extension of a randomized clinical study. Epilepsia. 2021;62(9):2142\u201350. https:\/\/doi.org\/10.1111\/epi.17007.","journal-title":"Epilepsia"},{"issue":"10","key":"1102_CR19","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1111\/epi.17724","volume":"64","author":"DG Vossler","year":"2023","unstructured":"Vossler DG, Rosenfeld WE, Stern S, et al. Sustainability of seizure reduction and seizure control with adjunctive cenobamate: post-hoc analysis of a phase 3, open-label study. Epilepsia. 2023;64(10):2644\u201352. https:\/\/doi.org\/10.1111\/epi.17724.","journal-title":"Epilepsia"},{"issue":"3","key":"1102_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/epi4.12346","volume":"4","author":"F Reinhardt","year":"2019","unstructured":"Reinhardt F, Weber YG, Mayer T, et al. Changes in drug load during lacosamide combination therapy: a noninterventional, observational study in German and Austrian clinical practice. Epilepsia Open. 2019;4(3):409\u201319. https:\/\/doi.org\/10.1002\/epi4.12346.","journal-title":"Epilepsia Open."},{"key":"1102_CR21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.eplepsyres.2016.08.018","volume":"127","author":"MJ Brodie","year":"2016","unstructured":"Brodie MJ, Whitesides J, Schiemann J, D\u2019Souza J, Johnson ME. Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: a pooled analysis from three phase III studies. Epilepsy Res. 2016;127:114\u20138. https:\/\/doi.org\/10.1016\/j.eplepsyres.2016.08.018.","journal-title":"Epilepsy Res"},{"issue":"3","key":"1102_CR22","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1212\/wnl.0000000000002864","volume":"87","author":"E Ben-Menachem","year":"2016","unstructured":"Ben-Menachem E, Mameniskiene R, Quarato PP, et al. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Neurology. 2016;87(3):314\u201323. https:\/\/doi.org\/10.1212\/wnl.0000000000002864.","journal-title":"Neurology"},{"issue":"3","key":"1102_CR23","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/epi.17426","volume":"64","author":"L Piccenna","year":"2023","unstructured":"Piccenna L, O\u2019Dwyer R, Leppik I, et al. Management of epilepsy in older adults: a critical review by the ILAE Task Force on Epilepsy in the elderly. Epilepsia. 2023;64(3):567\u201385. https:\/\/doi.org\/10.1111\/epi.17426.","journal-title":"Epilepsia"},{"key":"1102_CR24","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.eplepsyres.2014.11.015","volume":"110","author":"IE Leppik","year":"2015","unstructured":"Leppik IE, Wechsler RT, Williams B, Yang H, Zhou S, Laurenza A. Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials. Epilepsy Res. 2015;110:216\u201320. https:\/\/doi.org\/10.1016\/j.eplepsyres.2014.11.015.","journal-title":"Epilepsy Res"},{"key":"1102_CR25","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.eplepsyres.2017.10.022","volume":"138","author":"Y Haasum","year":"2017","unstructured":"Haasum Y, Johnell K. Use of antiepileptic drugs and risk of falls in old age: a systematic review. Epilepsy Res. 2017;138:98\u2013104. https:\/\/doi.org\/10.1016\/j.eplepsyres.2017.10.022.","journal-title":"Epilepsy Res"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-024-01102-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-024-01102-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-024-01102-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T20:52:17Z","timestamp":1710363137000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-024-01102-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1102"],"URL":"https:\/\/doi.org\/10.1007\/s40266-024-01102-3","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"16 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"O\u2019Dwyer R, et al. Safety and efficacy of cenobamate for the treatment of focal seizures in older patients. Presented at the American Epilepsy Society 2022 Annual Meeting, 2\u20136 December 2022, Nashville, TN, USA (Poster 1.292) and encored at the American Academy of Neurology 2023 Annual Meeting, 22\u201327 April 2023, Boston, MA, USA (Poster P4.002).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Previous presentation"}},{"value":"This study was supported by SK Life Science, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Rebecca O\u2019Dwyer is a consultant\/advisor for SK Life Science, Inc. Sean Stern, Clarence T. Wade, and Anuradha Guggilam are employees of SK Life Science, Inc. William E. Rosenfeld is a consultant\/advisor for SK Life Science, Inc.; speaker for SK Life Science, Inc.; and has received research support from SK Life Science, Inc. and UCB Pharma.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The original phase III study was conducted in accordance with the ethical principles of Good Clinical Practice, according to the International Conference on Harmonisation guidelines and all applicable country-specific regulations. The study protocol was approved by an independent Ethics Committee or Institutional Review Board at each site according to local regulations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from each patient prior to the original phase III study; no new patient consent was required for this post\u00a0hoc analysis.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data for the analyses described in this manuscript are available by request from the corresponding author or SK Life Science, Inc., the company sponsoring the clinical development of cenobamate for the treatment of focal epilepsy.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: RO, SS, CTW, AG, and WER. Acquisition of data: SS, CTW, and WER. Statistical analysis: SS and CTW. Data interpretation: RO, SS, CTW, AG, and WER. All authors were involved in critically revising the manuscript, reviewed the final manuscript, and gave approval for submission.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}